Mark A. Glickman, Chief Commercial Officer at Aralez Pharmaceuticals Inc. (ARLZ), bought 25,000 shares at $3.68 ($92K) on 2016-05-16, disclosed to the SEC on 2016-05-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| AUXL | SELL | 2014-11-24 | $1.6M | — | Filing → |